Your browser doesn't support javascript.
loading
Sex Differences in Outcomes of Tetralogy of Fallot Patients With Implantable Cardioverter-Defibrillators.
Waldmann, Victor; Bouzeman, Abdeslam; Duthoit, Guillaume; Koutbi, Linda; Bessière, Francis; Labombarda, Fabien; Marquié, Christelle; Gourraud, Jean-Baptiste; Mondoly, Pierre; Sellal, Jean Marc; Bordachar, Pierre; Hermida, Alexis; Al Arnaout, Alain; Anselme, Frédéric; Audinet, Caroline; Bernard, Yvette; Boveda, Serge; Bun, Sok Sithikun; Chassignolle, Morgane; Clerici, Gaël; Da Costa, Antoine; de Guillebon, Maxime; Defaye, Pascal; Elbaz, Nathalie; Eschalier, Romain; Garcia, Rodrigue; Guenancia, Charles; Guy-Moyat, Benoit; Halimi, Franck; Irles, Didier; Iserin, Laurence; Jourda, François; Ladouceur, Magalie; Lagrange, Philippe; Laredo, Mikael; Mansourati, Jacques; Massoulié, Grégoire; Mathiron, Amel; Maury, Philippe; Messali, Anne; Narayanan, Kumar; Nguyen, Cédric; Ninni, Sandro; Perier, Marie-Cécile; Pierre, Bertrand; Pujadas, Penelope; Sacher, Frédéric; Sagnol, Pascal; Sharifzadehgan, Ardalan; Walton, Camille.
Afiliação
  • Waldmann V; Université de Paris, INSERM, Paris Cardiovascular Research Centre, Paris, France; Adult Congenital Heart Disease Medico-Surgical Unit, European Georges Pompidou Hospital, Paris, France; Cardiac Electrophysiology Unit, European Georges Pompidou Hospital, Paris, France. Electronic address: victor.wald
  • Bouzeman A; Parly II Private Hospital, Le Chesnay, France.
  • Duthoit G; La Pitié-Salpêtrière University Hospital, Paris, France.
  • Koutbi L; La Timone Hospital, Marseille, France.
  • Bessière F; Louis Pradel Hospital, Lyon, France.
  • Labombarda F; Caen University Hospital, Caen, France.
  • Marquié C; Lille University Hospital, Lille, France.
  • Gourraud JB; Nantes University Hospital, Nantes, France.
  • Mondoly P; Toulouse University Hospital, Toulouse, France.
  • Sellal JM; Nancy University Hospital, Nancy, France.
  • Bordachar P; Bordeaux University Hospital, Bordeaux, France.
  • Hermida A; Amiens University Hospital, Amiens, France.
  • Al Arnaout A; La Rochelle Hospital, La Rochelle, France.
  • Anselme F; Rouen University Hospital, Rouen, France.
  • Audinet C; Bretagne Sud Hospital, Lorient, France.
  • Bernard Y; Besançon University Hospital, Besançon, France.
  • Boveda S; Pasteur Clinic, Toulouse, France.
  • Bun SS; Princess Grace Hospital, Monaco, France.
  • Chassignolle M; Université de Paris, INSERM, Paris Cardiovascular Research Centre, Paris, France.
  • Clerici G; Saint Pierre University Hospital, La Réunion, France.
  • Da Costa A; Saint Etienne University Hospital, Saint Etienne, France.
  • de Guillebon M; Pau Hospital, Pau, France.
  • Defaye P; Grenoble University Hospital, Grenoble, France.
  • Elbaz N; Henri-Mondor University Hospital, Créteil, France.
  • Eschalier R; Clermont Ferrand University Hospital, Clermont Ferrand, France.
  • Garcia R; Poitiers University Hospital, Poitiers, France.
  • Guenancia C; Dijon University Hospital, Dijon, France.
  • Guy-Moyat B; Limoges University Hospital, Limoges, France.
  • Halimi F; Parly II Private Hospital, Le Chesnay, France.
  • Irles D; Annecy Hospital, Annecy, France.
  • Iserin L; Adult Congenital Heart Disease Medico-Surgical Unit, European Georges Pompidou Hospital, Paris, France.
  • Jourda F; Auxerre Hospital, Auxerre, France.
  • Ladouceur M; Université de Paris, INSERM, Paris Cardiovascular Research Centre, Paris, France; Adult Congenital Heart Disease Medico-Surgical Unit, European Georges Pompidou Hospital, Paris, France.
  • Lagrange P; Saint-Pierre Clinic, Perpignan, France.
  • Laredo M; La Pitié-Salpêtrière University Hospital, Paris, France.
  • Mansourati J; Brest University Hospital, Brest, France.
  • Massoulié G; Clermont Ferrand University Hospital, Clermont Ferrand, France.
  • Mathiron A; Amiens University Hospital, Amiens, France.
  • Maury P; Toulouse University Hospital, Toulouse, France.
  • Messali A; Bichat University Hospital, Paris, France.
  • Narayanan K; Université de Paris, INSERM, Paris Cardiovascular Research Centre, Paris, France.
  • Nguyen C; Chalon sur Saône Hospital, Chalon sur Saône, France.
  • Ninni S; Lille University Hospital, Lille, France.
  • Perier MC; Université de Paris, INSERM, Paris Cardiovascular Research Centre, Paris, France.
  • Pierre B; Tours University Hospital, Tours, France.
  • Pujadas P; Les Franciscaines Clinic, Nîmes, France.
  • Sacher F; Bordeaux University Hospital, Bordeaux, France.
  • Sagnol P; Chalon sur Saône Hospital, Chalon sur Saône, France.
  • Sharifzadehgan A; Université de Paris, INSERM, Paris Cardiovascular Research Centre, Paris, France; Cardiac Electrophysiology Unit, European Georges Pompidou Hospital, Paris, France.
  • Walton C; Louis Pradel Hospital, Lyon, France.
JACC Clin Electrophysiol ; 8(10): 1304-1314, 2022 10.
Article em En | MEDLINE | ID: mdl-36266008
ABSTRACT

BACKGROUND:

Women with congenital heart disease at high risk for sudden cardiac death have been poorly studied thus far.

OBJECTIVES:

The aim of this study was to assess sex-related differences in patients with tetralogy of Fallot (TOF) and implantable cardioverter-defibrillators (ICDs).

METHODS:

Data were analyzed from the DAI-T4F (French National Registry of Patients With Tetralogy of Fallot and Implantable Cardioverter Defibrillator) cohort study, which has prospectively enrolled all patients with TOF with ICDs in France since 2010. Clinical events were centrally adjudicated by a blinded committee.

RESULTS:

A total of 165 patients (mean age 42.2 ± 13.3 years) were enrolled from 40 centers, including 49 women (29.7%). Among the 9,692 patients with TOF recorded in the national database, the proportion of women with ICDs was estimated to be 1.1% (95% CI 0.8%-1.5%) vs 2.2% (95% CI 1.8%-2.6%) in men (P < 0.001). The clinical profiles of patients at implantation, including the number of risk factors for ventricular arrhythmias, were similar between women and men. During a median follow-up period of 6.8 years (IQR 2.5-11.4 years), 78 patients (47.3%) received at least 1 appropriate ICD therapy, without significant difference in annual incidences between women (12.1%) and men (9.9%) (HR 1.22; 95% CI 0.76-1.97; P = 0.40). The risk for overall ICD-related complications was similar in women and men (HR 1.33; 95% CI 0.81-2.19; P = 0.30), with 24 women (49.0%) experiencing at least 1 complication.

CONCLUSIONS:

Our findings suggest that women with TOF at high risk for sudden cardiac death have similar benefit/risk balance from ICD therapy compared with men. Whether ICD therapy is equally offered to at-risk women vs men warrants further evaluation in TOF as well as in other congenital heart disease populations. (French National Registry of Patients With Tetralogy of Fallot and Implantable Cardioverter Defibrillator [DAI-T4F]; NCT03837574).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Tetralogia de Fallot / Desfibriladores Implantáveis / Cardiopatias Congênitas Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: JACC Clin Electrophysiol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Tetralogia de Fallot / Desfibriladores Implantáveis / Cardiopatias Congênitas Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: JACC Clin Electrophysiol Ano de publicação: 2022 Tipo de documento: Article